Literature DB >> 11849755

Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains.

Estifanos Ghebremedhin1, Dietmar R Thal, Christian Schultz, Heiko Braak.   

Abstract

The association between the K-variant of the butyrylcholinesterase gene (BCHE-K) and Alzheimer disease (AD) or AD-related neuropathology has been reported to date with conflicting results. Here, we determined in a sample of 521 cases the severity of AD-related neuropathology and the polymorphisms of both BCHE-K and apolipoprotein E (ApoE). Histopathologically, all brains were classified according to procedures permitting differentiation of the evolutionary stages of neurofibrillary tangles (NFTs) and amyloid-beta-protein deposition (A beta-deposits). The results show that the association between BCHE-K and AD-related neuropathology only was limited to homozygotes for the K allele (P=0.036 for NFTs, and P=0.045 for A beta-deposits) at ages > or = 70 years but not 50-69 years. Furthermore, no interaction was apparent between BCHE-K and ApoE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849755     DOI: 10.1016/s0304-3940(02)00014-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion.

Authors:  A Johansen; E-M D Nielsen; G Andersen; Y H Hamid; D P Jensen; C Glümer; T Drivsholm; K Borch-Johnsen; T Jørgensen; T Hansen; O Pedersen
Journal:  Diabetologia       Date:  2004-07-17       Impact factor: 10.122

2.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

3.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

4.  The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.

Authors:  Erez Podoly; Deborah E Shalev; Shani Shenhar-Tsarfaty; Estelle R Bennett; Einor Ben Assayag; Harvey Wilgus; Oded Livnah; Hermona Soreq
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.